The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

Journal of Leukocyte Biology

Volumn 95, Issue 1, 2014, Pages 95-104

  Peter, Barbara ^a,b   Cerny Reiterer, Sabine ^a   Hadzijusufovic, Emir ^a,b   Schuch, Karina ^a   Stefanzl, Gabriele ^a   Eisenwort, Gregor ^a   Gleixner, Karoline V ^a   Hoermann, Gregor ^a   Mayerhofer, Matthias ^a,c   Kundi, Michael ^d   Baumgartner, Sigrid ^a   Sperr, Wolfgang R ^a   Pickl, Winfried F ^a   Willmann, Michael ^b   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c HANUSCH HOSPITAL   (Austria)

^d Medical University of Vienna and Wiener Werkstaette for Suicide Research   (Austria)

Author keywords

Mastocytosis; Mcl 1; Targeted therapy

Indexed keywords

BIM PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; DASATINIB; MESSENGER RNA; MIDOSTAURIN; OBATOCLAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; MCL1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MYELOID LEUKEMIA FACTOR 1; ONCOPROTEIN; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL X; PYRROLE DERIVATIVE;

ADULT; AGED; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOMA CELL LINE; MICROSCOPY; MIDDLE AGED; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; VERY ELDERLY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MASTOCYTOSIS; MCL-1; MORTALITY; SARCOMA; TARGETED THERAPY; TUMOR CELL LINE;

MASTOCYTOSIS; MCL-1; TARGETED THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAST-CELL SARCOMA; MEMBRANE PROTEINS; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; RNA, MESSENGER;

EID: 84897019340     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.1112609     Document Type: Article

References (53)

1. Akin, C., Metcalfe, D. D. (2004) Systemic mastocytosis. Annu. Rev. Med. 55, 419-432.
2. Horny, H. P., Sotlar, K., Valent, P. (2007) Mastocytosis: state of the art. Pathobiology 74, 121-132.
3. Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin-Nelemans, H. C., Hamdy, N. A., Lortholary, O., Robyn, J., van Doormaal, J., Sotlar, K., Hauswirth, A. W., Arock, M., Hermine, O., Hellmann, A., Triggiani, M., Niedoszytko, M., Schwartz, L. B., Orfao, A., Horny, H. P., Metcalfe, D. D. (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 37, 435-453.
4. Metcalfe, D. D. (2008) Mast cells and mastocytosis. Blood 112, 46-56.
5. Arock, M., Valent, P. (2010) Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev. Hematol. 3, 497-516.
6. Valent, P., Horny, H. P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., Sperr, W. R., Wolff, K., Brunning, R. D., Parwaresch, R. M., Austen, K. F., Lennert, K., Metcalfe, D. D., Vardiman, J. W., Bennett, J. M. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of "Year 2000 Working Conference on Mastocytosis". Leuk. Res. 25, 603-625.
7. Valent, P., Horny, H. P., Li, C. Y., Longley, J. B., Metcalfe, D. D., Parwaresch, R. M., Bennett, J. M. (2001) Mastocytosis (mast cell disease). In World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues (S. Jaffe, E. L. Harris, N. Stein, H. W. Vardiman, eds.), J. International Agency for Research on Cancer, Lyon, France, 291-302.
8. Horny, H. P., Akin, C., Metcalfe, D. D., Escribano, L., Bennett, J. M., Valent, P., Bain, B. J. (2008) Mastocytosis (mast cell disease). In World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. (Swerdlow, S. H. Campo, E. Harris, N. L. Jaffe, E. S. Pileri, S. A. Stein, H. Thiele, J. Vardiman, eds.), J. W., International Agency for Research on Cancer, Lyon, France, 54-63.
9. Travis, W. D., Li, C. Y., Hoagland, H. C., Travis, L. B., Banks, P. M. (1986) Mast cell leukemia: report of a case and review of the literature. Majo. Clin. Proc. 61, 957-966.
10. Valent, P., Akin, C., Sperr, W. R., Escribano, L., Arock, M., Horny, H. P., Bennett, J. M., Metcalfe, D. D. (2003) Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk. Res. 27, 635-641.
11. Gotlib, J. (2006) KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol. Allergy Clin. North Am. 26, 575-592.
12. Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., Metcalfe, D. D. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92, 10560-10564.
13. Longley, B. J., Tyrrell, L., Lu, S. Z., Ma, Y. S., Langley, K., Ding, T. G., Duffy, T., Jacobs, P., Tang, L. H., Modlin, I. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12, 312-314.
14. Fritsche-Polanz, R., Jordan, J. H., Feix, A., Sperr, W. R., Sunder-Plassmann, G., Valent, P., Födinger, M. (2001) Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 113, 357-364.
15. Furitsu, T., Tsujimura, T., Tono, T., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., Kanayama, Y. (1993) IdentifIication of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J. Clin. Invest. 92, 1736-1744.
16. Mayerhofer, M., Gleixner, K. V., Hoelbl, A., Florian, S., Hoermann, G., Aichberger, K. J., Bilban, M., Esterbauer, H., Krauth, M. T., Sperr, W. R., Longley, J. B., Kralovics, R., Moriggl, R., Zappulla, J., Liblau, R. S., Schwarzinger, I., Sexl, V., Sillaber, C., Valent P. (2008) Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J. Immunol. 180, 5466-5476.
17. Growney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., Gilliland, D. G. (2005) Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106, 721-724.
18. Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S. L., Durocher, J. A., Lichy, J. H., Wang, Y., Cohen, P. S., Arber, D. A., Heinrich, M. C., Neckers, L., Galli, S. J., Gilliland, D. G., Coutré, S. E. (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106, 2865-2870.
19. Von Bubnoff, N., Gorantla, S. H., Kancha, R. K., Lordick, F., Peschel, C., Duyster, J. (2005) The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19, 1670-1671.
20. Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., Pickl, W. F., Sillaber, C., Valent, P. (2006) The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 107, 752-759.
21. Schittenhelm, M. M., Shiraga, S., Schroeder, A., Corbin, A. S., Griffith, D., Lee, F. Y., Bokemeyer, C., Deininger, M. W., Druker, B. J., Heinrich, M. C. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66, 473-481.
22. Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., Akin, C. (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108, 286-291.
23. Gleixner, K. V., Mayerhofer, M., Sonneck, K., Gruze, A., Samorapoompichit, P., Baumgartner, C., Lee, F. Y., Aichberger, K. J., Manley, P. W., Fabbro, D., Pickl, W. F., Sillaber, C., Valent, P. (2007) Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92, 1451-1459.
24. Purtill, D., Cooney, J., Sinniah, R., Carnley, B., Cull, G., Augustson, B., Cannell, P. (2008) Dasatinib therapy for systemic mastocytosis: four cases. Eur. J. Haematol. 80, 456-458.
25. Verstovsek, S., Tefferi, A., Cortes, J., O'Brien, S., Garcia-Manero, G., Pardanani, A., Akin, C., Faderl, S., Manshouri, T., Thomas, D., Kantarjian, H. (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin. Cancer Res. 14, 3906-3915.
26. Gotlib, J., DeAngelo, D. J., George, T. I., Corless, C. L., Linder, A., Langford, C., Dutreix, C., Gross, S., Nikolova, Z., Graubert, T. (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of fully accrued phase II trial. Blood 116, 144.
27. Valent, P., Ghannadan, M., Akin, C., Krauth, M. T., Selzer, E., Mayerhofer, M., Sperr, W. R., Arock, M., Samorapoompichit, P., Horny, H. P., Metcalfe, D. D. (2004) On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur. J. Clin. Invest. 34, 41-52.
28. Pardanani, A., Akin, C., Valent, P. (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract. Res. Clin. Haematol. 19, 595-615.
29. Cervero, C., Escribano, L., San Miguel, J. F., Díaz-Agustín, B., Bravo, P., Villarrubia, J., García-Sanz, R., Velasco, J. L., Herrera, P., Vargas, M., González, M., Navarro, J. L., Orfao, A. (1999) Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am. J. Hematol. 60, 191-195.
30. Mekori, Y. A., Gilfillan, A. M., Akin, C., Hartmann, K., Metcalfe, D. D. (2001) Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J. Clin. Immunol. 21, 171-174.
31. Jordan, J. H., Walchshofer, S., Jurecka, W., Mosberger, I., Sperr, W. R., Wolff, K., Chott, A., Bühring, H. J., Lechner, K., Horny, H. P., Valent, P. (2001) Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum. Pathol. 32, 545-552.
32. Baghestanian, M., Jordan, J. H., Kiener, H. P., Bevec, D., Agis, H., Fritsch, G., Müller, M. R., Bankl, H. C., Schernthaner, G. H., Lechner, K., Valent, P. (2002) Activation of human mast cells through stem cell factor receptor (KIT) is associated with expression of bcl-2. Int. Arch. Allergy Immunol. 129, 228-236.
33. Hartmann, K., Artuc, M., Baldus, S. E., Zirbes, T. K., Hermes, B., Thiele, J., Mekori, Y. A., Henz, B. M. (2003) Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am. J. Pathol. 163, 819-826.
34. Aichberger, K. J., Mayerhofer, M., Gleixner, K. V., Krauth, M. T., Gruze, A., Pickl, W. F., Wacheck, V., Selzer, E., Müllauer, L., Agis, H., Sillaber, C., Valent, P. (2007) Identification of MCL-1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL-1 antisense oligonucleotides and synergism with PKC412. Blood 109, 3031-3041.
35. Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., Stewart, A. K. (2007) Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109, 5430-5438.
36. Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., Viallet, J., Samudio, I., Andreeff, M. (2008) Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68, 3413-3420.
37. Azmi, A. S., Mohammad, R. M. (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell. Physiol. 218, 13-21.
38. Aichberger, K. J., Gleixner, K. V., Mirkina, I., Cerny-Reiterer, S., Peter, B., Ferenc, V., Kneidinger, M., Baumgartner, C., Mayerhofer, M., Gruze, A., Pickl, W. F., Sillaber, C., Valent, P. (2009) Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 114, 5342-5351.
39. Butterfield, J. H., Weiler, D., Dewald, G., Gleich, G. J. (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 12, 345-355.
40. Akin, C., Kirshenbaum, A. S., Semere, T., Worobec, A. S., Scott, L. M., Metcalfe, D. D. (2000) Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 28, 140-147.
41. Hoermann, G., Cerny-Reiterer, S., Perné, A., Klauser, M., Hoetzenecker, K., Klein, K., Müllauer, L., Gröger, M., Nijman, S. M., Klepetko, W., Valent, P., Mayerhofer, M. (2011) Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816Vpositive systemic mastocytosis. Am. J. Pathol. 178, 2344-2356.
42. Dolznig, H., Habermann, B., Stangl, K., Deiner, E. M., Moriggl, R., Beug, H., Müllner, E. W. (2002) Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr. Biol. 12, 1076-1085.
43. DeVinney, R., Gold, W. M. (1990) Establishment of two dog mastocytoma cell lines in continuous culture. Am. J. Respir. Cell Mol. Biol. 3, 413-420.
44. Valent, P., Ashman, L. K., Hinterberger, W., Eckersberger, F., Majdic, O., Lechner, K., Bettelheim, P. (1989) Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73, 1778-1785.
45. Rebuzzi, L., Willmann, M., Sonneck, K., Gleixner, K. V., Florian, S., Kondo, R., Mayerhofer, M., Vales, A., Gruze, A., Pickl, W. F., Thalhammer, J. G., Valent, P. (2007) Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet. Immunol. Immunopathol. 115, 320-333.
46. Van Cruchten, S., van Den Broeck, W. (2002) Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 31, 214-223.
47. Baumgartner, C., Gleixner, K. V., Peter, B., Ferenc, V., Gruze, A., Remsing Rix, L. L., Bennett, K. L., Samorapoompichit, P., Lee, F. Y., Pickl, W. F., Esterbauer, H., Sillaber, C., Superti-Furga, G., Valent, P. (2008) Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRα. Exp. Hematol. 36, 1244-1253.
48. Campas, C., Cosialls, A. M., Barragán, M., Iglesias-Serret, D., Santidrián, A. F., Coll-Mulet, L., de Frias, M., Domingo, A., Pons, G., Gil, J. (2006) Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp. Hematol. 34, 1663-1669.
49. Rahmani, M., Aust, M. M., Attkisson, E., Williams, D. C. Jr., Ferreira-Gonzalez, A., Grant, S. (2012) Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 119, 6089-6098.
50. Mott, J. L., Bronk, S. F., Mesa, R. A., Kaufmann, S. H., Gores, G. J. (2008) BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol. Cancer Ther. 7, 2339-2347.
51. Ekoff, M., Kaufmann, T., Engström, M., Motoyama, N., Villunger, A., Jönsson, J. I., Strasser, A., Nilsson, G. (2007) The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 110, 3209-3217.
52. Ustun, C., DeRemer, D. L., Akin, C. (2011) Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk. Res. 35, 1143-1152.
53. Buet, D., Gallais, I., Lauret, E., Denis, N., Lombard, B., Guillonneau, F., Kosmider, O., Loew, D., Dusanter-Fourt, I., Guillouf, C., Mayeux, P., Moreau-Gachelin, F. (2012) Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. Blood 119, 4228-4241.